"With Inari as the mechanical thrombectomy leader in pulmonary embolism (PE) and deep vein thrombosis (DVT), Inari's products could now bolster the neurovascular subsegment that represents a $1.3 ...

Inari Medical, Inc. NARI is well-poised for growth on the back of a huge market opportunity for its products and its commitment to understanding the venous system. However, the company’s dependency on ...

Learn more about whether Glaukos Corporation or Inari Medical, Inc. is a better investment based on AAII's A+ Investor grades ...

Key barriers in adhering to anticoagulation guidelines included uncertainty about its choice, established practices, and the ...

Inari Medical’s product portfolio includes medical devices that treat pulmonary embolism, deep vein thrombosis, in-stent thrombosis and arteriovenous fistula. Stryker said the products are “hi ...

Outpatient management of patients with cancer-associated pulmonary embolism (PE) may be a feasible, safe approach with low short-term rates of recurrent venous thromboembolism (VTE), major bleeding, ...

It includes mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism. “The acquisition of Inari expands Stryker's portfolio to ...

Inari Medical, Inc. NARI shares rallied ... such as deep vein thrombosis and pulmonary embolism. This company is expected to post quarterly loss of $0.04 per share in its upcoming report, which ...

Inari shareholders are getting a fair price ... and has not really been a player in venous markets like pulmonary embolism (or PE), deep vein thrombosis (or DVT), limb ischemia, and the like ...